Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options

Bariatric Surgery in NAFLD

(2022) Mahak Chauhan et al.   DIGESTIVE DISEASES AND SCIENCES

Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease

(2022) Yamei Duan et al.   Frontiers in Immunology

Global multi-stakeholder endorsement of the MAFLD definition

(2022) Nahum Méndez-Sánchez et al.   Lancet Gastroenterology & Hepatology

AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review

(2022) Michelle T. Long et al.   GASTROENTEROLOGY

Macronutrient and Micronutrient Intake in Adolescents with Non-Alcoholic Fatty Liver Disease: the Association with Disease Severity

(2022) Ariel Porto et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials

(2022) Danielle Lee et al.   Nutrients

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

(2021) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Interplay between diet and gut microbiome, and circulating concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men

(2021) Jun Li et al.   GUT

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

(2021) Ferenc Emil Mózes et al.   GUT

Non-alcoholic fatty liver disease

(2021) Elizabeth E Powell et al.   LANCET

A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis

(2021) Yongtao Xiao et al.   LIVER INTERNATIONAL

Therapeutic aspects of bile acid signalling in the gut‐liver axis

(2021) Benedikt Simbrunner et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease

(2021) Fasiha Kanwal et al.   GASTROENTEROLOGY

Population screening for liver fibrosis: towards early diagnosis and intervention for chronic liver diseases

(2021) Pere Ginès et al.   HEPATOLOGY

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

(2021) Annalisa Berzigotti et al.   JOURNAL OF HEPATOLOGY

24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation

(2021) Ci Zhu et al.   JOURNAL OF HEPATOLOGY

Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C

(2021) Pegah Golabi et al.   Annals of Hepatology

The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases

(2021) Lingxuan An et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Baveno VII – Renewing consensus in portal hypertension

(2021) Roberto de Franchis et al.   JOURNAL OF HEPATOLOGY

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

Higher intake of whole grains and dietary fiber are associated with lower risk of liver cancer and chronic liver disease mortality

(2021) Xing Liu et al.   Nature Communications

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study

(2021) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Akkermansia muciniphila Prevents Fatty Liver, Decreases Serum Triglycerides, and Maintains Gut Homeostasis

(2020) Sejeong Kim et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

(2020) A. Mantovani et al.   DIABETES & METABOLISM

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease

(2020) Silvia Sookoian et al.   GUT

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

(2020) Donatella Chianelli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics

(2020) Laurent Castera   LIVER INTERNATIONAL

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map

(2020) Jianhong Zhu et al.   Lancet Diabetes & Endocrinology

The microbiome modulating activity of bile acids

(2020) Yuan Tian et al.   Gut Microbes

Plasma levels of trimethylamine-N-oxide can be increased with ‘healthy’ and ‘unhealthy’ diets and do not correlate with the extent of atherosclerosis but with plaque instability

(2020) Yen Chin Koay et al.   CARDIOVASCULAR RESEARCH

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

(2020) Giovanni Targher et al.   GUT

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders

(2020) Judith Aron-Wisnewsky et al.   Nature Reviews Gastroenterology & Hepatology

From NAFLD to MAFLD: when pathophysiology succeeds

(2020) Herbert Tilg et al.   Nature Reviews Gastroenterology & Hepatology

Hepatic Stellate Cell–Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis

(2020) Michitaka Matsuda et al.   SEMINARS IN LIVER DISEASE

Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease

(2020) Tiangang Li et al.   Hepatobiliary Surgery and Nutrition

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)

(2020) Stefano Fiorucci et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis

(2020) Guillaume Lassailly et al.   GASTROENTEROLOGY

From NAFLD to MAFLD: Implications of a premature change in terminology

(2020) Zobair M Younossi et al.   HEPATOLOGY

Microbiomics, metabolomics, predicted metagenomics and hepatic steatosis in a population‐based study of 1355 adults

(2020) Louise JM Alferink et al.   HEPATOLOGY

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

(2020) Tracey G Simon et al.   GUT

MAFLD identifies patients with significant hepatic fibrosis better than NAFLD

(2020) Sakura Yamamura et al.   LIVER INTERNATIONAL

Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta‐analysis

(2020) Toon J. I. De Munck et al.   LIVER INTERNATIONAL

Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice

(2020) Sarah Alsamman et al.   Science Translational Medicine

Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD

(2020) Giljae Lee et al.   Nature Communications

Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

(2020) Alessandro Mantovani et al.   GUT

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis

(2019) Alessandro Mantovani et al.   LIVER INTERNATIONAL

Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

(2019) Ralph A DeFronzo et al.   Diabetes & Vascular Disease Research

Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis

(2019) Soumik BasuRay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans

(2019) Emmelie Cansby et al.   FASEB JOURNAL

Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis

(2019) Oriol Juanola et al.   FASEB JOURNAL

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study

(2019) Clara Depommier et al.   NATURE MEDICINE

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

(2019) Stefan Traussnigg et al.   Lancet Gastroenterology & Hepatology

Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction

(2019) Sifan Chen et al.   Cell Metabolism

Hepatocyte Stress Increases Expression of YAP and TAZ in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis

(2019) Meghan Mooring et al.   HEPATOLOGY

Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications

(2019) Claudio Tana et al.   International Journal of Environmental Research and Public Health

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Increased liver localization of lipopolysaccharides in human and experimental non‐alcoholic fatty liver disease

(2019) Guido Carpino et al.   HEPATOLOGY

Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis

(2019) Mohammad Shadab Siddiqui et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Circulating microbiome in blood of different circulatory compartments

(2018) Robert Schierwagen et al.   GUT

Endoplasmic Reticulum stress signaling and the pathogenesis of Non-Alcoholic Fatty Liver Disease

(2018) Cynthia Lebeaupin et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

(2018) Paolo Angeli et al.   JOURNAL OF HEPATOLOGY

Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women

(2018) Lesley Hoyles et al.   NATURE MEDICINE

The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD

(2018) Taylor K. Soderborg et al.   Nature Communications

How to Approach a Patient With Nonalcoholic Fatty Liver Disease

(2017) Herbert Tilg   GASTROENTEROLOGY

Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease

(2017) Oscar Chávez-Talavera et al.   GASTROENTEROLOGY

Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease

(2017) Feng Shen et al.   Hepatobiliary & Pancreatic Diseases International

The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation

(2017) Soumik BasuRay et al.   HEPATOLOGY

Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis

(2017) Guangqin Xiao et al.   HEPATOLOGY

Bi-directional analysis between fatty liver and cardiovascular disease risk factors

(2017) Jiantao Ma et al.   JOURNAL OF HEPATOLOGY

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

(2017) Hannes Hagström et al.   JOURNAL OF HEPATOLOGY

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

(2017) Giovanni Musso et al.   JAMA Internal Medicine

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk

(2016) Weifei Zhu et al.   CELL

Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis

(2016) Xiaobo Wang et al.   Cell Metabolism

STK25 is a critical determinant in nonalcoholic steatohepatitis

(2016) Manoj Amrutkar et al.   FASEB JOURNAL

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

(2016) Juan P. Arab et al.   HEPATOLOGY

Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis

(2016) Benjamin Lelouvier et al.   HEPATOLOGY

Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach

(2016) Federica Del Chierico et al.   HEPATOLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

(2016) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice

(2016) Hubert Plovier et al.   NATURE MEDICINE

NAFLD and diabetes mellitus

(2016) Herbert Tilg et al.   Nature Reviews Gastroenterology & Hepatology

The Role of Cholesterol in the Pathogenesis of NASH

(2016) George N. Ioannou   TRENDS IN ENDOCRINOLOGY AND METABOLISM

The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis

(2016) Mark A. Herman et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Quantifying the Association Between Physical Activity and Cardiovascular Disease and Diabetes: A Systematic Review and Meta‐Analysis

(2016) Ahad Wahid et al.   Journal of the American Heart Association

Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults

(2016) Yu-ming Chen et al.   Scientific Reports

Protein kinase STK25 controls lipid partitioning in hepatocytes and correlates with liver fat content in humans

(2015) Manoj Amrutkar et al.   DIABETOLOGIA

Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH

(2015) Manoj Amrutkar et al.   FASEB JOURNAL

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels

(2015) Paola Portillo-Sanchez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Short-chain fatty acids in control of body weight and insulin sensitivity

(2015) Emanuel E. Canfora et al.   Nature Reviews Endocrinology

Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice

(2014) Jing Liu et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

PNPLA3 mediates hepatocyte triacylglycerol remodeling

(2014) Hanna Ruhanen et al.   JOURNAL OF LIPID RESEARCH

Alterations of the human gut microbiome in liver cirrhosis

(2014) Nan Qin et al.   NATURE

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease

(2013) Maitreyi Raman et al.   Clinical Gastroenterology and Hepatology

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk

(2013) W.H. Wilson Tang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study

(2012) L. Gerber et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease

(2012) Hae-Ki Min et al.   Cell Metabolism

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

(2012) Rohit Loomba et al.   HEPATOLOGY

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

(2012) Lixin Zhu et al.   HEPATOLOGY

Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease

(2011) Kristin D Kistler et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

(2011) Michael R. Charlton et al.   GASTROENTEROLOGY

Characterization of fecal microbial communities in patients with liver cirrhosis

(2011) Yanfei Chen et al.   HEPATOLOGY

Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut

(2011) Ekihiro Seki et al.   JOURNAL OF PHYSIOLOGY-LONDON

Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease

(2011) N. Kumashiro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bacterial flavin-containing monooxygenase is trimethylamine monooxygenase

(2011) Y. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crosstalk of reactive oxygen species and NF-κB signaling

(2010) Michael J Morgan et al.   CELL RESEARCH

Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies

(2010) Joe West et al.   GASTROENTEROLOGY

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor   expression

(2010) A. R. Moschen et al.   GUT

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

(2010) Mustafa S. Ascha et al.   HEPATOLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance

(2010) Giovanni Tarantino   WORLD JOURNAL OF GASTROENTEROLOGY

Histopathology of nonalcoholic fatty liver disease

(2010) Elizabeth M Brunt   WORLD JOURNAL OF GASTROENTEROLOGY

Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression

(2009) Alexander R. Moschen et al.   JOURNAL OF HEPATOLOGY

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

(2008) Guruprasad P. Aithal et al.   GASTROENTEROLOGY

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

(2008) Stefano Romeo et al.   NATURE GENETICS